Natera reports Q1 EPS (50c), consensus (66c)

Reports Q1 revenue $501.8M, consensus $446.67M. “We delivered another strong quarter, with volume growth across the business, including a record growth quarter for Signatera (NTRA),” said Steve Chapman, chief executive officer of Natera. “Our progress reflects the strength of our technology and the breadth and quality of the clinical data. With multiple high-impact datasets reading out and trials underway, we believe we’re in a strong position to help millions of patients in the future.”